SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Imipenem / Cilastatin / Relebactam Formula-
tion

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier
Trade name : Imipenem / Cilastatin / Relebactam Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against
Use of the Substance/Mixture : Pharmaceutical

1.3 Details of the supplier of the safety data sheet
Company : MSD
Piercetown
A86 HD21 Dunboyne, Ireland
Telephone : 908-740-4000
E-mail address of person responsible for the SDS : EHSDATASTEWARD@msd.com

1.4 Emergency telephone number
1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

- Eye irritation, Category 2
- Respiratory sensitisation, Category 1
- Reproductive toxicity, Category 2
- Specific target organ toxicity - repeated exposure, Category 2
- Short-term (acute) aquatic hazard, Category 1
- Long-term (chronic) aquatic hazard, Category 1

H319: Causes serious eye irritation.
H334: May cause allergy or asthma symptoms or breathing difficulties if inhaled.
H361d: Suspected of damaging the unborn child.
H373: May cause damage to organs through pro-
longed or repeated exposure.
H400: Very toxic to aquatic life.
H410: Very toxic to aquatic life with long lasting
effects.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms : 

Signal word : Danger
Hazard statements : H319 Causes serious eye irritation.
Imipenem / Cilastatin / Relebactam Formulation

Precautionary statements:

**Prevention:**
- P260 Do not breathe dust.
- P273 Avoid release to the environment.
- P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

**Response:**
- P304 + P340 IF INHALED: Remove person to fresh air and keep comfortable for breathing.
- P308 + P313 IF exposed or concerned: Get medical advice/ attention.
- P391 Collect spillage.

Hazardous components which must be listed on the label:
- Imipenem
- Relebactam

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

### SECTION 3: Composition/information on ingredients

#### 3.2 Mixtures

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No. EC-No. Index-No. Registration number</th>
<th>Classification</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cilastatin</td>
<td>81129-83-1 279-694-4</td>
<td>Eye Irrit. 2; H319</td>
<td>&gt;= 30 - &lt; 50</td>
</tr>
</tbody>
</table>
SECTION 4: First aid measures

4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled : If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.

In case of eye contact : In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention.

If swallowed : If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.
4.2 Most important symptoms and effects, both acute and delayed

Risks:
- Causes serious eye irritation.
- May cause allergy or asthma symptoms or breathing difficulties if inhaled.
- Suspected of damaging the unborn child.
- May cause damage to organs through prolonged or repeated exposure.
- Excessive exposure may aggravate preexisting asthma and other respiratory disorders (e.g. emphysema, bronchitis, reactive airways dysfunction syndrome).
- Contact with dust can cause mechanical irritation or drying of the skin.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment:
- Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media:
- Water spray
- Alcohol-resistant foam
- Carbon dioxide (CO2)
- Dry chemical

Unsuitable extinguishing media:
- None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during firefighting:
- Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
- Exposure to combustion products may be a hazard to health.

Hazardous combustion products:
- Carbon oxides
- Metal oxides

5.3 Advice for firefighters

Special protective equipment for firefighters:
- In the event of fire, wear self-contained breathing apparatus.
- Use personal protective equipment.

Specific extinguishing methods:
- Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
- Use water spray to cool unopened containers.
- Remove undamaged containers from fire area if it is safe to do so.
- Evacuate area.
SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions: Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions: Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up: Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures: Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation: Use only with adequate ventilation.

Advice on safe handling: Do not breathe dust. Do not swallow. Do not get in eyes. Avoid prolonged or repeated contact with skin. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
Keep container tightly closed. Already sensitised individuals should consult their physician regarding working with respiratory irritants or sensitisers. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers: Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.

Advice on common storage: Do not store with the following product types: Strong oxidizing agents

7.3 Specific end use(s)

Specific use(s): No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cilastatin</td>
<td>81129-83-1</td>
<td>TWA</td>
<td>5 mg/m³ (OEB 1)</td>
<td>Internal</td>
</tr>
<tr>
<td>Imipenem</td>
<td>74431-23-5</td>
<td>TWA</td>
<td>1000 ug/m³ (OEB 1)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Further information: RSEN</td>
<td></td>
</tr>
<tr>
<td>Relebactam</td>
<td>1174020-13-3</td>
<td>TWA</td>
<td>0.3 mg/m³ (OEB 2)</td>
<td>Internal</td>
</tr>
</tbody>
</table>

8.2 Exposure controls

Engineering measures
Use feasible engineering controls to minimize exposure to compound. All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Imipenem / Cilastatin / Relebactam Formula-
tion

Version 3.12  Revision Date: 27.08.2021  SDS Number: 68822-00024  Date of last issue: 09.04.2021
Date of first issue: 27.02.2015

Personal protective equipment
Eye protection: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Hand protection
Material: Chemical-resistant gloves

Skin and body protection
Work uniform or laboratory coat.

Respiratory protection
If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection. Equipment should conform to I.S. EN 143
Filter type: Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state: powder
Colour: White to light yellow
Odour: No data available
Odour Threshold: No data available
Melting point/freezing point: No data available
Initial boiling point and boiling range: No data available
Flammability (solid, gas): May form explosive dust-air mixture during processing, handling or other means.

Flammability (liquids): Not applicable
Upper explosion limit / Upper flammability limit: No data available
Lower explosion limit / Lower flammability limit: No data available
Flash point: Not applicable
Auto-ignition temperature: No data available
Decomposition temperature: No data available
pH: No data available
Viscosity
Viscosity, dynamic: No data available
Viscosity, kinematic: Not applicable
Imipenem / Cilastatin / Relebactam Formula-
tion

Solubility(ies)
Water solubility : soluble

Partition coefficient: n-octanol/water : Not applicable
Vapour pressure : Not applicable
Relative density : No data available
Density : No data available
Relative vapour density : Not applicable
Particle characteristics
Particle size : No data available

9.2 Other information
Explosives : Not explosive
Oxidizing properties : The substance or mixture is not classified as oxidizing.
Evaporation rate : Not applicable
Molecular weight : No data available

SECTION 10: Stability and reactivity

10.1 Reactivity
Not classified as a reactivity hazard.

10.2 Chemical stability
Stable under normal conditions.

10.3 Possibility of hazardous reactions
Hazardous reactions : May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.

10.4 Conditions to avoid
Conditions to avoid : Heat, flames and sparks. Avoid dust formation.

10.5 Incompatible materials
Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products
No hazardous decomposition products are known.
SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of exposure:
- Inhalation
- Skin contact
- Ingestion
- Eye contact

Acute toxicity
Not classified based on available information.

Components:

Cilastatin:
Acute oral toxicity:
- LD50 (Rat): > 10,000 mg/kg
- LD50 (Mouse): > 10,000 mg/kg

Imipenem:
Acute oral toxicity:
- LD50 (Mouse): 10,000 mg/kg

Acute toxicity (other routes of administration):
- LD50 (Rat): > 2,000 mg/kg
- Application Route: Intravenous
- LD50 (Mouse): 1,500 mg/kg
- Application Route: Intravenous

Skin corrosion/irritation
Not classified based on available information.

Components:

Cilastatin:
Species: Rabbit
Result: No skin irritation

Relebactam:
Method: EpiDerm
Result: No skin irritation

Serious eye damage/eye irritation
Causes serious eye irritation.

Components:

Cilastatin:
Species: Rabbit
Result: Moderate eye irritation
Imipenem / Cilastatin / Relebactam Formula-
tion

Relebactam:
Method : Bovine cornea (BCOP)
Result : No eye irritation

Respiratory or skin sensitisation

Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
May cause allergy or asthma symptoms or breathing difficulties if inhaled.

Components:

Cilastatin:
Exposure routes : Skin contact
Remarks : No data available

Imipenem:
Remarks : May cause sensitisation of susceptible persons by inhalation of aerosol or dust.

Exposure routes : Skin contact
Remarks : Not classified due to lack of data.

Relebactam:
Test Type : Local lymph node assay (LLNA)
Exposure routes : Dermal
Result : Not a skin sensitizer.

Germ cell mutagenicity
Not classified based on available information.

Components:

Cilastatin:
Genotoxicity in vitro : Test Type: Microbial mutagenesis assay (Ames test)
Result: negative

Imipenem:
Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test
Test system: Chinese hamster lung cells
Result: negative

Test Type: reverse mutation assay
Result: negative
### Imipenem / Cilastatin / Relebactam Formula-
**tion**

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.12</td>
<td>27.08.2021</td>
<td>68822-00024</td>
<td>09.04.2021</td>
<td>27.02.2015</td>
</tr>
</tbody>
</table>

#### Test Type:
- **unscheduled DNA synthesis assay**
  - Result: negative

- **Chromosomal aberration**
  - Result: negative

- **sister chromatid exchange assay**
  - Result: negative

#### Genotoxicity in vivo:
- **In vivo micronucleus test**
  - Species: Mouse
  - Application Route: Intravenous
  - Result: negative

### Relebactam:

#### Genotoxicity in vitro:
- **Bacterial reverse mutation assay (AMES)**
  - Result: negative

- **Chromosome aberration test in vitro**
  - Result: negative

#### Genotoxicity in vivo:
- **Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)**
  - Species: Rat
  - Application Route: Intraperitoneal injection
  - Result: negative

#### Germ cell mutagenicity- Assessment:
- Weight of evidence does not support classification as a germ cell mutagen.

### Carcinogenicity
Not classified based on available information.

### Reproductive toxicity
Suspected of damaging the unborn child.

### Components:

#### Cilastatin:

**Effects on fertility**
- **Fertility/early embryonic development**
  - Application Route: Intravenous
  - LOAEL: 1,000 mg/kg body weight
  - No adverse effects detected.

#### Imipenem:

**Effects on fertility**
- **Fertility/early embryonic development**
  - Species: Rat, male and female
  - Application Route: Intravenous
  - LOAEL: 80 mg/kg body weight
Symptoms: No adverse effects, Reduced foetal weight
Result: No effects on fertility and early embryonic development were detected.

Test Type: Fertility/early embryonic development
Species: Rat, male and female
Application Route: Subcutaneous
Fertility: LOAEL: 320 mg/kg body weight

Symptoms: No adverse effects, Reduced foetal weight
Result: No effects on fertility and early embryonic development were detected.

Effects on foetal development:

: Test Type: Development
Species: Monkey
Application Route: Intravenous
Developmental Toxicity: LOAEL: 100 mg/kg body weight
Result: Embryotoxic effects and adverse effects on the offspring were detected., No teratogenic effects

Test Type: Development
Species: Rabbit
Application Route: Intravenous
Developmental Toxicity: NOAEL: 60 mg/kg body weight
Result: No teratogenic effects

Test Type: Development
Species: Rat
Application Route: Intravenous
Developmental Toxicity: NOAEL: 60 mg/kg body weight
Result: No teratogenic effects

Reproductive toxicity - Assessment:

: Some evidence of adverse effects on development, based on animal experiments.

Relebactam:

Effects on fertility:

: Test Type: Pre-/postnatal development
Species: Rat
Application Route: Subcutaneous
Fertility: NOAEL: 450 mg/kg body weight

Effects on foetal development:

: Test Type: Embryo-foetal development
Species: Rat
Application Route: Intraperitoneal injection
Embryo-foetal toxicity: NOAEL: 450 mg/kg body weight
Result: No effects on foetal development

Test Type: Embryo-foetal development
Species: Mouse
Application Route: Intraperitoneal injection
Embryo-foetal toxicity: NOAEL: 450 mg/kg body weight
Result: No effects on foetal development
Test Type: Development
Species: Rat
Application Route: Intravenous
Developmental Toxicity: NOAEL: \( \geq 450 \) mg/kg body weight
Result: No effects on fertility and early embryonic development were detected.

Test Type: Development
Species: Rabbit
Application Route: Intravenous
Developmental Toxicity: NOAEL: 450 mg/kg body weight
Result: No effects on foetal development

**STOT - single exposure**
Not classified based on available information.

**STOT - repeated exposure**
May cause damage to organs through prolonged or repeated exposure.

### Components:

**Relebactam:**

- **Target Organs**: Kidney
- **Assessment**: May cause damage to organs through prolonged or repeated exposure.

### Repeated dose toxicity

**Components:**

**Cilastatin:**

- **Species**: Rat
- **NOAEL**: \( \geq 500 \) mg/kg
- **Application Route**: Intravenous
- **Exposure time**: 90 Days
- **Remarks**: No significant adverse effects were reported

- **Species**: Monkey
- **NOAEL**: \( \geq 500 \) mg/kg
- **Application Route**: Intravenous
- **Exposure time**: 5 Weeks
- **Remarks**: No significant adverse effects were reported

**Imipenem:**

- **Species**: Monkey
- **NOAEL**: 60 mg/kg
- **LOAEL**: 150 mg/kg
- **Application Route**: Intravenous
- **Exposure time**: 6 Months
- **Target Organs**: Kidney

- **Species**: Monkey
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Imipenem / Cilastatin / Relebactam Formula-
tion

NOAEL: 120 mg/kg
Application Route: Subcutaneous
Exposure time: 6 Months
Remarks: No significant adverse effects were reported

Species: Rat
NOAEL: 180 mg/kg
Application Route: Intravenous
Exposure time: 6 Months
Remarks: No significant adverse effects were reported

Species: Rabbit
LOAEL: 150 mg/kg
Application Route: Intravenous
Target Organs: Kidney

Relebactam:
Species: Rat, female
NOAEL: 150 mg/kg
Application Route: Intravenous
Exposure time: 30 d

Species: Rat, male
NOAEL: 450 mg/kg
Application Route: Intravenous
Exposure time: 30 d

Species: Monkey
NOAEL: 25 mg/kg
Application Route: Intravenous
Exposure time: 30 d
Target Organs: Kidney

Species: Monkey
NOAEL: 37.5 mg/kg
Application Route: Intravenous
Exposure time: 30 d

Species: Monkey
NOAEL: 50 mg/kg
LOAEL: 150 mg/kg
Application Route: Intravenous
Exposure time: 3 Months
Target Organs: Kidney

Aspiration toxicity
Not classified based on available information.
11.2 Information on other hazards

Endocrine disrupting properties

**Product:**
**Assessment:** The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Experience with human exposure

**Components:**

**Imipenem:**
- **Inhalation:** Symptoms: Nausea, Vomiting, Diarrhoea, Fever, hypotension, Dizziness, Drowsiness, Convulsions, pruritis, Rash
- **Remarks:** May cause sensitisation of susceptible persons by inhalation of aerosol or dust.

**Relebactam:**
- **Skin contact:** Symptoms: Pain, Discomfort, Diarrhoea, Abdominal pain, insomnia, Nausea, sore throat, Vertigo

SECTION 12: Ecological information

12.1 Toxicity

**Components:**

**Cilastatin:**
- **Toxicity to fish**
  - LC50 (Pimephales promelas (fathead minnow)): > 111 mg/l
  - Exposure time: 96 h
  - Method: OECD Test Guideline 203

- **Toxicity to daphnia and other aquatic invertebrates**
  - EC50 (Daphnia magna (Water flea)): > 99 mg/l
  - Exposure time: 48 h
  - Method: OECD Test Guideline 202

- **Toxicity to algae/aquatic plants**
  - EC50 (Anabaena flos-aquae): > 99 mg/l
  - Exposure time: 72 h
  - Method: OECD Test Guideline 201

  - EC50 (Pseudokirchneriella subcapitata (green algae)): > 99 mg/l
  - Exposure time: 72 h
  - Method: OECD Test Guideline 201

  - NOEC (Anabaena flos-aquae): 99 mg/l
  - Exposure time: 72 h
  - Method: OECD Test Guideline 201
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Imipenem / Cilastatin / Relebactam Formula-
tion

Version 3.12
Revision Date: 27.08.2021
SDS Number: 68822-00024
Date of last issue: 09.04.2021
Date of first issue: 27.02.2015

NOEC (Pseudokirchneriella subcapitata (green algae)): 99 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

Toxicity to microorganisms: EC50: > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Toxicity to fish (Chronic toxicity): EC10: > 9.9 mg/l
Exposure time: 32 d
Species: Pimephales promelas (fathead minnow)
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity): EC10: > 10 mg/l
Exposure time: 21 d
Species: Daphnia magna (Water flea)
Method: OECD Test Guideline 211

Imipenem:

Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): > 78 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants: EC50 (Anabaena flos-aquae (cyanobacterium)): 0.0046 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Anabaena flos-aquae (cyanobacterium)): 0.002 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

EC50 (Pseudokirchneriella subcapitata (green algae)): > 74 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 74 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

M-Factor (Acute aquatic toxicity): 100

Toxicity to microorganisms: EC50: > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209
Imipenem / Cilastatin / Relebactam Formula-
tion

Toxicity to fish (Chronic toxicity)
NOEC: 9.4 mg/l
Exposure time: 32 d
Species: Pimephales promelas (fathead minnow)
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)
NOEC: 11 mg/l
Exposure time: 21 d
Species: Daphnia magna (Water flea)
Method: OECD Test Guideline 211

M-Factor (Chronic aquatic toxicity): 10

Relebactam:

Toxicity to daphnia and other aquatic invertebrates
EC50 (Daphnia magna (Water flea)): > 100 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

EC50 (Americamysis): > 100 mg/l
Exposure time: 96 h

Toxicity to algae/aquatic plants
EC50 (Pseudokirchneriella subcapitata (green algae)): 86 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 12 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

EC50 (Anabaena flos-aquae (cyanobacterium)): > 11 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Anabaena flos-aquae (cyanobacterium)): 11 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

Toxicity to microorganisms
EC50: > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

NOEC: 96.3 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Toxicity to fish (Chronic toxicity)
NOEC: 9.2 mg/l
Exposure time: 32 d
Species: Pimephales promelas (fathead minnow)
Method: OECD Test Guideline 210
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity):
- NOEC: 2.7 mg/l
- Exposure time: 21 d
- Species: Daphnia magna (Water flea)
- Method: OECD Test Guideline 211

12.2 Persistence and degradability

Components:

Cilastatin:
- Biodegradability: Result: Not readily biodegradable.
  - Biodegradation: 27 %
  - Exposure time: 28 d
  - Method: OECD Test Guideline 301B

Imipenem:
- Biodegradability: Result: Not readily biodegradable.
  - Biodegradation: 29 %
  - Exposure time: 28 d
  - Method: OECD Test Guideline 301B

Relebactam:
- Biodegradability: Result: Not readily biodegradable.
  - Biodegradation: 11.3 %
  - Exposure time: 28 d
  - Method: OECD Test Guideline 314

12.3 Bioaccumulative potential

Components:

Cilastatin:
- Partition coefficient: n-octanol/water: log Pow: -3.53

Imipenem:
- Partition coefficient: n-octanol/water: log Pow: < -1

Relebactam:
- Partition coefficient: n-octanol/water: log Pow: < -2

12.4 Mobility in soil

Components:

Cilastatin:
- Distribution among environmental compartments: log Koc: 2.3

Relebactam:
Distribution among environmental compartments:

\[ \log Koc = 2.3 \]

12.5 Results of PBT and vPvB assessment

**Product:**
**Assessment:** This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Endocrine disrupting properties

**Product:**
**Assessment:** The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

12.7 Other adverse effects

No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

**Product:** Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.

**Contaminated packaging:** Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number

**ADN:** UN 3077
**ADR:** UN 3077
**RID:** UN 3077
**IMDG:** UN 3077
**IATA:** UN 3077

14.2 UN proper shipping name

**ADN:** ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Imipenem / Cilastatin / Relebactam Formula-
tion

Version 3.12  Revision Date: 27.08.2021  SDS Number: 68822-00024

Date of last issue: 09.04.2021  Date of first issue: 27.02.2015

ADR : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Imipenem)

RID : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Imipenem)

IMDG : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Imipenem)

IATA : Environmentally hazardous substance, solid, n.o.s. (Imipenem)

14.3 Transport hazard class(es)

ADN : 9
ADR : 9
RID : 9
IMDG : 9
IATA : 9

14.4 Packing group

ADN
Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9

ADR
Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9
Tunnel restriction code : (-)

RID
Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9

IMDG
Packing group : III
Labels : 9
EmS Code : F-A, S-F

IATA (Cargo)
Packing instruction (cargo aircraft) : 956
Packing instruction (LQ) : Y956
Packing group : III
Imipenem / Cilastatin / Relebactam Formula- tion

14.5 Environmental hazards

ADN
Environmentally hazardous : yes

ADR
Environmentally hazardous : yes

RID
Environmentally hazardous : yes

IMDG
Marine pollutant : yes

IATA (Passenger)
Environmentally hazardous : yes

IATA (Cargo)
Environmentally hazardous : yes

14.6 Special precautions for user
The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Maritime transport in bulk according to IMO instruments
Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII) : Not applicable
REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59). : Not applicable
Regulation (EC) No 1005/2009 on substances that deplete the ozone layer : Not applicable
Regulation (EU) 2019/1021 on persistent organic pollutants (recast) : Not applicable
Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals : Not applicable
REACH - List of substances subject to authorisation (Annex XIV) : Not applicable
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Imipenem / Cilastatin / Relebactam Formula-
tion

Version 3.12 Revision Date: 27.08.2021 SDS Number: 68822-00024 Date of last issue: 09.04.2021
Date of first issue: 27.02.2015


E1 ENVIRONMENTAL HAZARDS

Quantity 1 Quantity 2
100 t 200 t

Other regulations:
Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable.
Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

The components of this product are reported in the following inventories:

AICS : not determined
DSL : not determined
IECSC : not determined

15.2 Chemical safety assessment
A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements

H319 : Causes serious eye irritation.
H334 : May cause allergy or asthma symptoms or breathing difficul-
ties if inhaled.
H361d : Suspected of damaging the unborn child.
H373 : May cause damage to organs through prolonged or repeated exposure.
H400 : Very toxic to aquatic life.
H410 : Very toxic to aquatic life with long lasting effects.

Full text of other abbreviations

Aquatic Acute : Short-term (acute) aquatic hazard
Aquatic Chronic : Long-term (chronic) aquatic hazard
Eye Irrit. : Eye irritation
Repr. : Reproductive toxicity
Resp. Sens. : Respiratory sensitisation
STOT RE : Specific target organ toxicity - repeated exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN -
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Imipenem / Cilastatin / Relebactam Formula-
tion

Version 3.12 Revision Date: 27.08.2021 SDS Number: 68822-00024 Date of last issue: 09.04.2021 Date of first issue: 27.02.2015

Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50% of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances Control Act (United States); TCSI - Technical Rule for Hazardous Substances; THS - Toxic Substances Control Act (United States); TSCA - United States; vPvB - Very Persistent and Very Bioaccumulative

Further information


Classification of the mixture:

Eye Irrit. 2 H319 Calculation method
Resp. Sens. 1 H334 Calculation method
Repr. 2 H361d Calculation method
STOT RE 2 H373 Calculation method
Aquatic Acute 1 H400 Calculation method
Aquatic Chronic 1 H410 Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.
Imipenem / Cilastatin / Relebactam Formula-
tion

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.12</td>
<td>27.08.2021</td>
<td>68822-00024</td>
<td>09.04.2021</td>
</tr>
</tbody>
</table>

Date of first issue: 27.02.2015